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INTRODUCTION 
 
In 2012, an estimate of 14.1 million new diagnosed cancer cases occurred 
globally with a total of 8.2 million cancer related deaths worldwide. Oral 
cancers are among the ten most common malignancies worldwide, the highest 
prevalence of which is noted in developing countries where a high prevalence 
of tobacco consumption still exists. The highest incidence of oral malignancy is 
in South – Central Asia and in Melanesia (1).  
The occurrence of oral malignancies in these individuals is multi-factorial with 
tobacco usage and alcohol consumption being predominant causes. Over the 
past two to three decades there has been a trend towards younger age of 
presentation with oral carcinoma. When diagnosed early, these patients have 
less morbidity but when diagnosed late, morbidity of both the surgery and post 
operative complications increases. A significant post operative complication 
that occurs is surgical site infection which can eventually lead to reconstruction 
flap failure and gross morbidity. Multiple risk factors are associated with these 
surgical site infections and attempts have been made to decrease the incidence 
of wound infections. 
Triclosan has been used in the medical profession for a number of years. It has 
been used to coat polyglactin sutures with the sole goal to decrease wound 
infections. When used at other surgical sites like the abdominal cavity and 
thorax, it has shown to decrease the infection rate at the surgical site 
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significantly. Triclosan coated sutures and its effect were never studied in the 
oral cavity. The oral cavity in itself is different from other parts of the body and 
so are the wounds. Microbial colonization of the oral cavity in the presence of a 
malignancy has never been studied. Whether it is the same as that in a normal 
oral cavity is not known. Only a thorough understanding of the colonization can 
effectively lead to reduction in these infections that cause gross morbidity to 
patients who undergo surgical procedures. 
This study aims to study the infection rates when this suture (triclosan coated 
polyglactin 910 suture) is used within the oral cavity following oral malignancy 
surgeries. This study also aims to understand further the oral microbiology that 
exists in the oral cavity of those who have a pre-existing malignancy with 
microbiological analysis of post operative wound infections in these patients. 
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OBJECTIVES 
 
1. The primary objective is to compare reduction of wound infection rate in 
Triclosan coated polyglactin 910 sutures as compared to plain coated 
polyglactin sutures in patients with oral malignancy treated in the unit over the 
past one year. 
 
2. The secondary objective is to include a microbiological study of all these 
patients in relation to wound infection. 
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LITERATURE REVIEW 
Cancer is responsible for causing more deaths in present age than 
cerebrovascular accidents and coronary artery diseases. The global cancer 
burden is progressively increasing with the WHO estimating 20 million new 
cases of cancers by the year 2025. Oral malignancies are among the top ten 
most common malignancies in the world with the highest prevalence being in 
the South – Central Asian and Melanesia population. In 2012, 2.1% of all 
cancers globally were malignancies involving the lips and the oral cavity. These 
malignancies were more common in men with a incidence of 22.9 per 100000 
in men and 16.9 per 100000 in women in areas of high incidence namely 
Melanesia. There were a total of 145000 deaths as a direct result of which 77% 
occurred in less developed countries with a lower economical status(1).  
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In India, there is an average of 100,000 new cases of oral cancer each year with 
Bhopal reporting the highest incidence with 10.9 per 100,000 and 9.6 per 
100,000 for tongue and mouth cancer respectively(2).  Head and neck cancers 
contribute to a substantial mortality in South Asian region. In 2010,  the 
estimated welfare and economically loss was estimated to be USD 16.9 
billion(3). The 5 year survival rate for advanced oral cancer is 20% (4) with the 
causes of death usually being loco-regional recurrence or distant metastasis, 
early diagnosis and detection of oral cancers can bring down the mortality rate 
significantly as the 5 year survival for early oral cancer is 80% (5). 
 
 
Anatomy and physiology of the oral cavity: 
The oral cavity is formed by the lips, tongue, the cheeks and the floor of the 
mouth.  It is bounded anteriorly by the vermilion border of the lips, inferiorly 
by the circumvallate papilla on the posterior third of the tongue. The superior 
border is at the junction between the hard and the soft palate with the lateral 
borders being formed by the anterior tonsillar pillars(6)(7).  
The embryological development of the head and the neck starts in the 4
th
 to 5
th
 
week of development from the 1
st
 and the 2
nd
 pharyngeal arches. The center of 
the face is formed by the stomodeum around which exists the first pharyngeal 
pouch. Each pharyngeal pouch contains three components – epithelial 
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endoderm, core of mesenchymal tissue and the surface ectoderm. The 
mesenchymal tissue is responsible for the formation of the muscular 
components of the face, while the neural crest cells within the mesenchymal 
core forming the skeletonal structures of the pharyngeal arch. Around the 
stomodeum by 42 weeks, develop caudially the maxillary prominences, 
laterally the maxillary and cranially the frontonasal prominences, which further 
undergo differentiation to lead to formation of the face(8). 
PROMINENCE STRUCTURES FORMED 
Frontonasal Medial and lateral nasal prominence, forehead, bridge of nose. 
Maxillary Lateral portion of the upper lip, cheeks 
Medial Nasal Tip of the nose, crest, philtrum of the upper lip 
Lateral Nasal Nasal alar 
Mandibular  Lower lip 
 
FIRST PHARYNGEAL ARCH – MANDIBULAR 
Nerve – maxillary and mandibular branch of the Trigeminal nerve 
Muscles – Forms the mylohyoid, tensor palpatine, tensor tympani and the 
anterior belly of the digastrics and all the muscles responsible for mastication 
namely – medial and lateral pterygoids, temporalis and masseter.  
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Skeletonal component – It forms the mandible, malleus, incus, 
sphenomandibular ligament, anterior ligament of malleus, premaxilla, maxilla, 
zygomatic bone and a portion of the temporal bone. 
SECOND PHARYNGEAL ARCH – HYOID: 
 Nerve – Forms the facial nerve 
Muscles – The mesenchymal core forms the posterior belly of the digastrics, 
stylohyoid, stapedius and all the muscles of facial expression namely – the 
orbicularis oculi, orbicularis oris, platysma, buccinators, auricularis and the 
frontalis.  
Skeletonal component – It forms the lesser horn and the upper half portion of 
the hyoid bone, stylohyoid ligament, styloid process and the stapes. 
The tongue starts developes at around the 4
th
 week from two lateral lingual 
swellings and one medial swelling which is called the tuberculum impar. The 
copula or the hypobrachial prominence forms a second median swelling which 
is formed from the second, third and fourth arches. The posterior part of the 
fourth arch marks the origin of the third median swelling which forms the 
epiglottis. The lateral lingual swellings overtake the growth of the first medial 
swelling to form the anterior 2/3rds of the tongue. The anterior 2/3rds of the 
tongue is covered by mucosa derived from the first pharyngeal arch – the 
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mandibular branch of the trigeminal nerve. The posterior third of the tongue 
derive its mucosa from the fourth pharyngeal arch(8). 
The primary palate develops when the two medial nasal prominences fuse in the 
midline and forms the intermaxillary segment. The secondary palate is formed 
by fusion of the palate plates which arise from the maxillary process. This 
segment forms the primary palate when it grows posteriorly and fuses with the 
secondary palate at the incisive foramen. 
Histologically, the entire oral cavity is lined by thick stratified squamous 
epithelial with the lamina propria acting as a supporting layer(9). The freely 
mobile mucosal lined surfaces namely – the floor of the mouth, underside of the 
tongue, cheeks and lips are lined by non keratinized squamous epithelial. 
Epithelium over the gingivae, hard palapte and the uppersurface of the tongue 
are highly keratinized. Below the epithelial lining there are thick collagenous 
submucosal layer which contains accessory salivary glands. The submucosal 
layer over the bone is thin. 
Anatomically the entire oral cavity can be divided into seven sub-divisions as 
below(10): 
- Anterior two-thirds of the tongue 
- Retromolar trigone 
- Alveolar sulcus 
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- Lips 
- Buccal mucosa 
- Hard palate 
- Floor of the mouth 
This traditional grouping has not been productive either for clinical medicine 
with regard to giving insight regarding etiological factors or techniques for 
examining the mouth.  
A rough rule of thumb exists for location of oral cancer which is as follows – 
one quarter occur in the most anterior portion of the floor of the mouth, one 
quarter occur in each of the gingivobuccal sulcus and the last quarter in the 
other locations of the mouth. This forms a horseshoe area in the oral cavity 
where occurs the highest predominance of cancerous oral lesions(11).  
Majority of saliva produced is from the major salivary glands namely the 
submandibular, parotid and the sublingual glands. The saliva once released 
from the glands forms a thin film like layer over the entire oral cavity. Besides 
lubricating the oral mucosa and protecting it from abrasive lesions, it also has 
antibacterial and antifungal properties. It prevents dental caries formation, 
attrition, and dental erosions(12). IgG, IgA and IgM antibodies are found 
abundantly in saliva and contribute to local oral immunity(13). Lederman in his 
paper titled the anatomy of cancer refers to two bulbous areas on either side of 
the tongue, known as the Lederman‟s oral mucus reservoirs. This oral mucus 
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reservoir are bounded by the gingivobuccal sulcus on either side, posteriorly by 
the tonsillar pillars, the medial border being formed by the posterior part of the 
tongue and is continous anteriorly with the floor of the mouth. There is 
stagnation of saliva in the gingivobuccal sulcus and the floor of the mouth 
which act as the reservoir and the gutter system in the oral cavity. This area is 
also responsible for pooling of saliva in an upright individual. This reservoir 
includes the horseshoe area where the majority of oral malignancies occur most 
commonly within the oral cavity(11)(14). 
 
Microbiology:  
The oral cavity has a diversion bacterial flora, it is important to understand the 
normal microflora in the oral cavity prior to understanding the flora in a 
diseased oral cavity. To our knowledge, there is preferential colonization of 
sites in the oral cavity with site specific adhesions on the bacterial surface, 
which enables it to bind to specific sites on the oral surface(15). A study 
conducted by Aas et al to define the bacterial growth from nine different sites in 
the oral cavities of normal healthy adults revealed the following six phyla(16): 
- Firmicutes : Streptococcus, Selenomonas, Gemella, Veillonella, 
Eubacterium  
- Actinobacteria: Actinomyces, Rothia 
-  Proteobacteria:  Neisseria, Campylobacter 
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-  Bacteroidetes 
-  Fusobacteria: Fusobacterium, Leptotrichia 
- TM7 
These were broadly divided into Gram positive and gram negative organisms, 
then further into anaerobic and aerobic organisms. 
The organisms that were cultured from the surgical sites in the oral cavity after 
head and neck cancer surgeries were polymicrobial and included 
Staphylococcus aureus (17), Pseudomonas aeruginosa, actineobacter (18), 
Escherichia coli, Klebsiella, non hemolytic Streptococcus, coagulase negative 
staphylococcus (19) to name a few.    
 
Premalignant conditions of the oral cavity: 
In 1805, suggestions were given to a European panel, that there are a group of 
benign diseases that will if followed for a prolonged duration will lead to 
invasive malignancy. This was the beginning of the concept of pre-cancer. In 
1870s, Sir James Paget described “smokers patch” also commonly now known 
as leucokeratosis(20). The World Health Organisation defined them as 
potentially malignant disorders which defined to two groups: 
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- Any tissue that has been morphologically altered such that it is at 
higher risk of becoming malignant than its otherwise normal 
counterpart is called a precancerous lesion. 
- Precancerous condition is a state that is associated with a higher risk 
of malignancy 
These premalignant lesions inspite of their clinical appearance are diagnosed 
only based on histology. The limitation occurs that even histology will only 
provide insight into whether the lesion has malignant potential and never 
predict malignant transformation(21). The risk of transformation into 
malignancy from a precancerous lesion has been reported between 6.6% to 
36.4%.(22) 
Potentially Malignant Disorders (PMDs) (23) 
Premalignant lesions  Premalignant conditions  
Leukoplakia  Lichen planus  
Erythroplakia  Discoid lupus erythematosus  
Proliferative verrucous leukoplakia(PVL)  Epidermolysis bullosa  
Viadent leukoplakia  Verruciform xanthoma  
Candida leukoplakia  Graft-versus-host-disease  
Reverse smokings‟ palate  Cheilitis glandularis  
Verrucous hyperplasia  Xeroderma pigmentosum  
Oral verrucous carcinoma  Syphilis (third stage)  
Dyskeratosis congenita  Plummer-Vinson syndrome  
Actinic cheilosis  Malnutrition  
Keratoacanthoma  Vitamin A, B, C deficiency  
Oral submucous fibrosis  Immunosuppressive diseases [AIDS]  
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Carcinogenesis: 
The mechanism of carcinogenesis in the oral cavity is a multifocal highly 
complex process. It occurs when several genetic alterations occur on the 
squamous epithelium.  
 
Normal oral mucosa 
Papillary hyperplasia 
Mild dysplasia 
                                             Moderate dysplasia 
                                                Severe dysplasia 
Carcinoma in situ 
Invasive carcinoma 
Field cancerization has been noted in tissues lined by either squamous 
epithelium as in the oral cavity or transitional epithelial as in the urinary 
bladder. It refers to the ability of cancer to develop at multiple sites. Over the 
years, there are various sites of malignant transformation within the oral cavity. 
Mutations in the tumour suppressor p53 genes have been noted in areas of 
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premalignant lesions and in the foci of carcinoma(24). Dysregulation of 
miRNA which are classified as proto-oncogenes are also involved in inhibition 
of differentiation, causes uncontrolled cell proliferation, and induces invasive 
behavior within cells and its progression to oral cancer(25). 
Smoking, alcohol and other exogenous factors over prolong durations of 
exposure can cause mutational expressions and multifocal presentations of 
tumor suppressor genes. These mutational adaptations may also change the 
level of resistance to therapy. 
 
Risk factors: 
There are multiple risk factors that all contribute to the development of oral 
malignancy. These factors may either be independent risk factors or may be 
additive to increasing the risk of development of oral cancer.  
Alcohol consumption has been associated with an increase in the risk of 
squamous cell carcinomas of the upper aerodigestive tract and also an increase 
in the risk of adenocarcinomas in the pancreas, distal stomach and colon – the 
later association being not as strong as the former. A study conducted by 
Thomas et al showed that there with increasing amounts of alcohol 
consumption there was an increased risk of malignancy. There was also an 
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increase in both pharyngeal and oral cancers in regular and heavy consumers of 
alcohol(26)(27). 
The risk of oropharyngeal cancers increases with duration of smoking 
cigarettes, number of cigarettes smoked per day in addition to the manner in 
which it is smoked. If smoked in the form of unfiltered cigarettes or in the form 
of cigars there is a further increased risk as when compared to smoking of 
filtered cigarettes(28). The smoking of one cigar is equivalent to smoking an 
entire pack of unfiltered cigarettes(29). In individuals who have quit smoking 
cigarettes for 10 years or more, the cessation has been associated with a sharp 
decrease in the risk of cancer. The reduction in the relative risk of development 
of oral and pharyngeal cancer suggests that smoking may play a role in the late 
stage of oropharyngeal carcinogenesis. 
The action of alcohol and smoking on the overall risk appear to be greater than 
additive and is more a multiplicative effect. These two carcinogens exhibit a 
biological synergism, where alcohol potentiates the action of the carcinogens in 
the cigarette smoke. There a 35-fold increase among the individuals who 
consumed more than four alcoholic drinks per day and two or more packs of 
cigarettes(28). Inspite of this biological synergism, it is evident that in the 
absence of smoking, alcohol independently increases the risk or pharyngeal and 
oral malignancy.  
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Tobacco usage and the chewing of betel quid has been in found in association 
with alcohol consumption to all contribute to the development of oral squamous 
cell carcinoma. There has also been a statistically significant association with 
betel nut chewing and oral cancer, the risk of which is increased if the betel nut 
quid is kept in the oral cavity and juices swallowed. A study conducted by Ko 
YC et al in Taiwan concluded that in the presence of all these three – smoking, 
alcohol consumption and betel nut chewing, there was a 123-fold increase in 
the incidence of oral cancer(30). 
Oral hygiene, dentition, jagged teeth, decayed teeth have been thought to 
increase the risk of development of oral malignancy.  In a case-control study 
conducted by Talamini et al, there was evidence that a poor general oral 
hygiene (dental caries and tartar)  had a 4.5 fold more in cases than among 
controls even after giving allowance for factors such as smoking, drinking , 
fruit and vegetable consumption(31).  Another case-control study conducted by 
Zheng et al, noted that in men who had reportedly never brushed their teeth an 
increase in the risk of oral malignancy by 7-fold.  These studies also confirmed 
that oral hygiene is an independent risk factor for development of oral 
cancer(32).  
Numerous studies preformed have shown a protective effect of high fruit diet 
with a reduction in oral cancer risk of 20-80%(33). The consumption of certain 
spicy food and hot beverages that are specific to certain cultures and indigenous 
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areas have shown to increase the overall risk of oral malignancy. In a case-
control study conducted in India by Notani et al, the use of red chilli powder 
was an risk factor for cancers of the aerodigestive system. It also emerged that 
consuming hot beverages increased the risk of oesophageal and pharyngeal 
cancers(34). In Brazil, an indigenous variety of tea, chimarrao and mate has 
been associated with an increase in the risk of only tongue cancer(35), there 
was no increase risk with consumption of tea or coffee. Notani et al also 
showed the protective effect of consumption of fish, vegetables, buttermilk and 
pulses. These factors were risk modifiers to those who chewed or smoked 
tobacco. 
The human papillomavirus (HPV) has been found to be associated with the 
progression to oral malignancies. HPV positive squamous cell carcinomas are 
characteristically different from HPV negative head and neck cancers with 
respect to genetic alterations, clinical progression and therapeutic response(36). 
A study performed at the University of Iowa, aimed at looking at whether HPV 
found in the oral exfoliate cells of the oral cavity was an individual risk factor 
for the development of oral malignancies. They found that in those infected by 
the oncogenic HPV or HPV-HR (most commonly HPV16) was independent of 
tobacco and alcohol use(37) but did act synergistically with alcohol(38). Their 
conclusion was that HPV testing could thus be predictive of HPV related head 
and neck cancers. A systemic review and meta-analysis done by Ndiaye et al, 
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there was prevalence of 24.2% of HPV-DNA in the oral cavity. In view of this 
high prevalence especially of HPV16, there may be benefit of prophylactic 
vaccinations(39).   
 
Staging of the disease: 
Once the diagnosis of an oral malignancy has been made, evaluation for 
locoregional and systemic spread are carried out following which the disease is 
clinically staged. Imaging modalities like magnetic resonance imaging, 
computed tomography can be applied when the disease is more advanced and 
will provide a more accurate T (tumour) and N (nodal) staging. Whenever 
clinical findings are unclear or uncertain, appropriate imaging modalities is to 
be utilized. The nodal status for all patients must be evaluated thoroughly in the 
pretreatment phase. It is also to be noted that nodes more than 3cm are not to be 
considered as single nodes but as a confluence of multiple nodes or as tumour 
within the soft tissues of the neck itself. 
The most common sites of metastasis in head and neck malignancies are the 
lungs and the bone with hepatic and brain metastasis been less frequent. 
Mediastinal nodes are considered distant metastasis. Metastatic workup in the 
pretreatment phase is crucial in cases of advanced disease(40)(41). 
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For patients with early disease with Stage I and II, the 5 year survival is as high 
as 80%. This drops as the disease becomes more advance with Stage III and IV 
having a 5 year survival of 40%(42). 
Management: 
Oral malignancy if diagnosed early is completely treatable. The primary goal of 
treatment is to cure the disease, preserving functionality is also of avid 
importance. Nerves are the most important structure to preserve if functionality 
is to be preserved. In early head and neck malignancies, there is a single 
modality of treatment namely either surgery or radiation therapy, ant the 
outcomes are both comparable. More advanced cases are discussed with a 
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multidisciplinary team so as to attain individualized patient treatment prior to 
making any treatment plans. 
Currently there are three modalities of treatment: 
- Surgical 
- Radiation therapy 
- Chemotherapy 
 
1. Surgery: 
In oral cavity tumors the goal of treatment is maximum tumour resection 
while being able to maintain functionality. The main treatment modality 
is surgical resection. To ensure an adequate surgical resection one must 
attain a resection margin of atleast 1-1.5cm. For early lesions, the defect 
closure can be done in multiple ways: 
 Primary closure 
 Split-thickness skin graft 
 Temporoparietal fascial flap 
For larger defects, following resections – glossectomy (total/partial), 
mandibulectomy(hemi/marginal) primary closure is not feasible.  
Reconstruction methods employed include:  
 Rotational flaps: 
   Nasolabial flap 
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   Facial artery musculomucosal flap (FAMM) 
   Submental artery island flap 
   Forehead flap 
   Deltopectoral flap 
  Pedicled flaps: 
   Pectoralis major myocutaneous flap 
   Latissmus dorsi myocutaneous flap 
 Free flap reconstructions: 
   Radial forearm free flap 
   Fibula osseocutaneous free flap 
If multiple nodes are involved, large nodes with extracapsular extension, 
then neck dissections are performed. Based on the number of structures 
spared and the nodal levels cleared, three are characterized, namely: 
- Radical neck dissection: Level I – V nodes cleared 
Spinal accessory nerve scarificed 
Sternocleidomastoid removed 
Internal jugular vein scarificed 
- Modified radical neck dissection: Level I – V cleared. 
Spinal accessory, sternocleidomastoid and internal jugular 
vein all spared.  
- Selective neck dissection: In oral malignancy, this is representative of 
supraomohyoid neck dissection, which consists of clearance of 
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cervical lymph nodes in level I-III while preserving the internal 
jugular vein, sternocleidomastoid and the spinal accessory nerve. 
 
2. Radiation Therapy: 
Radiation therapy may be administered as external beam radiation, 
brachytherapy (primary interstitial brachytherapy), intensity modulated 
radiation therapy (IMRT).  Radiation though can be given as primary 
treatment for oral malignancy is only rarely given so. It is usually 
reserved for post operative treatment in those patients who have a higher 
risk of local and regional recurrence. These include patients with a 
positive tumour margin, close resection margins (less than 1cm), large 
tumours (T3 or T4), perineural or perivascular invasion, tumour with 
greater than 4mm depth of invasion, nodal metastasis with extension 
beyond the capsule and multiple lymph nodal involvement. If any of 
these are present there is an indication for post operative radiation 
therapy with any of the modalities mentioned. 
 
 
3. Chemotherapy:  
Over the past few years, chemotherapy has been playing a more 
important role in the management of head and neck malignancies. It is 
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currently being used in advanced cases, unresectable tumors or in tumor 
recurrences.  
 
 
 
Wound infection: 
There are limitations of surgery in head and neck cancers are related to the risk 
of peri-operative complications.  In patients with oral malignancy, the 
occurrence of infection can lead to multiple difficulties including prolonged 
hospitalization, poor cosmetic outcomes, delay in initiation of adjuvant therapy 
and wastage of financial supports. In patients who underwent radical neck 
dissections as part of treatment for oral malignancy, infection rates without 
antimicrobial prophylaxis have been reported to be as high as 68%(43), which 
on giving antibiotic prophylaxis have decreased to 21%(17) – 41.8%(19). 
The Center for Disease Control, has classified surgical wounds into four 
categories based on the degrees of contamination, degree of inflammation, 
whether the gastrointestinal system/respiratory or urogenital system has been 
opened.  
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There are classified into four categories(44): 
1. Class I / Clean wounds:  
This is a completely uninfected operative wound, where there is no 
inflammation and the respiratory, gastrointestinal or uninfected urinary 
tract is not entered. These wounds are usually primarily closed.  Skin 
incision wounds following blunt trauma are included in this category. 
 
2. Class II / Clean – contaminated wounds: 
In these wounds, there is no major break in the sterile technique, it is 
done in a controlled manner. So any operative wound where the 
urogenital, gastrointestinal or respiratory system are opened without 
unexpected contamination. These include operations of the biliary 
tract, appendix, oropharynx and vagina. 
 
3. Class III / Contaminated wounds: 
Wounds that are fresh, open accidental wounds, this includes 
operations where there is a breach in the sterile techniques or spillage 
from the gastrointestinal tract. Incisions where acute, non-purulent 
inflammation is noted also is classified in this category. 
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4. Class IV / Dirty infected wounds:  
Wounds secondary to trauma that contain the devitalized tissue and 
also involves ongoing clinical infection or perforation of viscera. 
This means that organisms that cause post operative infection were in 
the operating field at the initiation of the operation. 
 
 Oral surgery is conducted in a clean-contaminated surgical field, as the oral 
cavity is continuously bathed in oral secretions that are rich in microflora. The 
oral gutters allows for stagnation of saliva in the inferior alveolar ridges and at 
the floor of the oral cavity. In a study conducted looking at sites of wound 
infection following surgery for oral malignancy, the site for highest occurrence 
of infections were the gingiva of the lower alveolar ridge and the base of the 
tongue(18). The relationship between the stagnation of saliva and infection has 
not been studied and is still uncertain.  
The Center for Disease Control have defined superficial surgical site infections 
as any infection that occurs within 30 days following surgery and must include 
one of the following: 
- The incision site should have purulent discharge 
- Aseptically obtained culture of the tissue or fluid from the incision 
site should contain organism isolates. 
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- There should be atleast one of the following – redness, warmth, 
tenderness, pain or localized swelling and the incision site is opened 
by the surgeon. This is not included if the culture attained are 
negative for isolates of organisms. 
- If the surgeon or attending physician make the diagnosis of 
superficial surgical site infection. 
It was also important that stitch abscesses and incisional surgical site infections 
that extended into the fascial or muscular planes were not included. 
 
Causes for wound infection: 
There are numerous factors that may lead to an increase in the incidence of 
wound infections post operatively. These risk factors included diabetes, poor 
nutritional status, prior chemotherapy or radiation therapy, dental status, 
preoperative hospital stay, stage of the disease, intra-operative blood 
transfusions, flap reconstructions and preoperative tracheostomies. The validity 
of each of these risk factors is questionable with various studies evaluating 
different factors.   
A study conducted to evaluate for risk factors for infection following oral 
surgery revealed that the only patient dependent factor for infection was male 
sex(18). There were no other patient factors namely smoking, tobacco usage or 
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alcohol consumption that had any significant association with an increase in 
infection rates. Another study conducted by Cloke et al concluded that there 
was no statistical significance in infection rates with age, sex or consumption of 
alcohol or smoking cigarettes(17). 
An increase in the risk of infection has been noted with various disease 
characteristics. These disease include the preoperative T (tumour) stage and the 
location of the primary tumour.  The most frequent site of infection in oral 
malignancy occurred when the primary tumour was located at the lower 
alveolar ridge. The second most common site was the base of the tongue(18).  
Tumours that occurred primarily on the tongue had the lowest risk of infection. 
The initial T(tumour) staging of the tumour also plays an important role in the 
overall outcome of the patient. Patients with advanced tumours (T4) lesions had 
to undergo more extensive dissections which leads to a greater chance of 
development of wound infections. These extensive surgical resection also leave 
large defect that require a larger reconstruction which are thus more 
predisposed to wound infections(19). A few studies the significance of the 
increasing N (nodal) staging has been associated with an increase in the wound 
infection rate(45), Penel et al(19) and Belusic-Gobic et al(18) did not report 
similar findings. 
The surgical procedure in itself has also shown to alter the rate of infections. In 
those patients who underwent reconstructive surgeries there was an increase in 
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the wound infection rate than those who underwent a primary wound 
closure(45)(19).  The wound infection rate in those where reconstruction was 
done with either using a muscular flap or a myocutaneous flap ranged from 20 – 
37%(46). The infection rates in those whose surgical sites were either closed 
primarily or a skin graft had infection rates of only 3-15%(18). The cause of 
this could be attributed to surgical errors either in flap construction or in 
hemostasis of the flap in itself. Among all the flap reconstructions, the 
pectoralis  major myocutaneous flap has been associated with a higher 
incidence of wound infections(18). Ischemia and flap necrosis predispose to 
infections and maybe caused by multiple factors. These factors include 
inadequate hemostasis, poorly mobilized grafts that are under undue tension 
due to inadequate tunneling, vascular insufficiency or direct tissue trauma. 
Ensuring proper flap planning and reducing technical errors could contribute to 
decreasing the infection rate in these major reconstructive surgeries.  
 
Intraoperative blood transfusions have been found to be associated with an 
increased risk of wound infection but whose statistically significance has not 
been proven. In the study conducted by Belusic-gobic et al, it was associated 
with 88.67% of wound infections(18)(47). 
Two studies preformed looked at the preoperative platelet count and its 
association with risk of surgical site infections in head and neck malignancies. 
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Schwartz et al and Pelczar et al reported that thrombocytosis was associated 
with an increase in the risk of wound infection. Platelets of more than 300000 
in Schwartz study and 400000 in Pelczar study were seen to be a statically 
significant cause for increase in the infection rate(48)(49). 
The history of preoperative radiation therapy and the wound infection rates is 
conflicting. Girod et al conducted a multicenteric study with 159 patients 
undergoing aerodigestive head and neck cancer surgeons with 87% of cases 
being located in the oral cavity and the oropharyngeal cavity. In the study the 
history of previous radiation therapy was statistically significant unlike in other 
studies(19). Robbins et al studied 400 patients who underwent major head and 
neck tumour resections and found no association between wound complication 
and radiation(45). 
 Penel et al studied the risk factors for wound infection for 165 consecutive 
cases over the duration of 24 months(19). They reported that in patients who 
had received preoperative chemotherapy the risk of wound infection was 68% 
which was reduced to 37% in those who did not receive chemotherapy. This 
finding was consistent with the study conducted by Corey et al where he 
observed surgical complications with patients who were receiving 
chemotherapy(50).  
There was an association of wound infection with those patients who had a 
longer duration of pre-operative stay or previous hospitalizations. This was also 
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linked to infection with resistant organisms – either intrinsic resistance or 
acquired antibiotic resistant organisms. (51) 
In most studies there was no association found between the dental status of a 
patient and the risk of wound infection following surgery. One prospective 
study of 186 head and neck malignancy patients conducted by Chaukar et al at 
the Tata memorial center reported that a significant factor associated with 
wound infection was oral hygiene and that preoperative scaling and good oral 
hygiene practices are to be considered for reduction in wound 
complications(52).    
High risk of wound infections following head and neck surgeries thus is an 
adequate indication for antibiotic prophylaxis in the perioperative period. It is 
now routine to adminster antibiotics for atleast 48 hours in the post operative 
period and this has shown to decrease infections from 78 to 33%(53). The 
current recommendation is to adminster one of the following(54): 
-  Cefazolin and metronidazole 
-  Cefuroxime and metronidazole 
- Ampicillin-sulbactam 
- Clindamycin in those allergic to beta-lactam drugs. 
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Consequences of wound infection: 
As a consequence of wound infection following surgery, there was an increase 
in the total duration of hospital stay, the total cost of treatment and the delay in 
initiation of post operative adjuvant radiation therapy.  
The median duration of hospital stay in patients who had wound infection 
increased from 18 days to 34 days(19). Penel et al also studied the prognostic 
significance after head and neck cancer surgeries. In 95 patients studied the 
total wound infection rate was 50.5%, the median duration of post operative 
stay in patients was 15 days, which in the setting of wound infection went up to 
a median of 29 days. There was also a delay in the initiation of radiation in 21 
out of 33 patients that required radiation therapy(55).  
Inspite of the large amount of morbidity following these surgeries, the overall 
prognosis and outcome were the same irrespective of wound related 
complications. 
 
 
TRICLOSAN:  
Triclosan is a chlorinated, aromatic compound with the chemical name 
trichlorohydroxydiphenyl ether. The product was registered as a pesticide by 
the Environmental protection agency in 1969(56). 
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Triclosan was introduced as a antimicrobial agent into the industrial market in 
1972(57) and its use was confined to the health care sector as a component in 
surgical scrubs(58). Over the coming years following approval from the Food 
and Drug Adminstration(FDA) and the Environmental Protection Agency(EPA)  
triclosan found broad application in the commercial market due to its 
antimicrobial properties. It thereafter has been incorporated into numerous 
personnel care and commercial products including soaps, toothpastes, 
cosmetics, deodorants, kitchen ware and children toys(56) as its action is 
efficacious against organisms in the oral cavity and the skin.   
The organic compound in addition to its antibacterial properties, also exhibits 
antifungal action.  At higher concentration, it acts as a bactericidal agent while 
it has bactertiostatic properities at lower concentrations. 
Chemistry and Mechanism of action: 
Triclosan is a chlorated bisphenol which is classified as a Class III drug by the 
FDA. The organic compound is a white solid powdered solid which has a mild 
phenolic odour. The compound contains two functional groups namely the 
phenol and the ether group. 
The chemical formula : C12H7Cl3O2        
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 Molecular structure:           
 
Triclosan acts as an antagonist to the active site(FabI) of the enoyl-acyl carrier 
reductase enzyme. The enzyme is essential in the fatty acid synthesis in 
bacteria, which is crucial for cell wall synthesis and cellular functionality of the 
bacteria(59). The formation of this FabI - NAD
+
 - Triclosan complex is 
responsible for the efficacy of triclosan as an antibacterial agent(60).  
 
Safety and Use in humans: 
The enoyl-acyl reductase enzyme is absent in humans and thus renders triclosan 
fairly safe for use in humans. The routes of administration to humans are either 
predominantly oral or dermal.  
Metabolism of triclosan within the body: 
 When used orally either in the form of toothpaste or mouthwashes, there 
0.08mcg/g of saliva of triclosan for upto 8 hours(61). In a study preformed 
using humans and rats after 24hours of local application of dermal triclosan, 
humans demonstrated 6.3% absorption as compared to 23% absorption seen in 
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rats. As the compound passes through skin, it is metabolized in the liver where 
it undergoes both glucuronidation and sulphation and is excreted via the renal 
system as triclosan glucuronide and triclosan sulphate. There were no active 
oxidative metabolites present in urine samples or in dermal samples(62).  When 
administered orally and once absorbed, the plasma concentration are raised 
within 1-3hours. The terminal plasma half life is approximately 21 hours and 
within the first 24hours most of the triclosan has been eliminated. The baseline 
urinary concentration was reached within 1 week and 54% of the total triclosan 
was eliminated in urine within 4 days(63).   
Triclosan showed high concentrations in the liver followed by the adipose 
tissues. The bioaccumulation for triclosan is low which confers safety in its 
usage.    
Toxicity – There are rare reports of acute toxicity in terms of contact dermatitis 
and photosensitivity following exposure to triclosan(64).  
 
Environmental Risks 
Triclosan is water and lipid soluble and involatile. The cause for the high 
concentration of triclosan is secondary to high urinary concentration which 
enters the sewage system directly from unmonitored use of triclosan in 
commercial industries. During the water treatments, there is biodegradation of 
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triclosan of which a low level is desorbed from this aqueous form to become a 
surface water effluent. These effluents have a tendency to attach to any solid 
sediments within the aqueous medium resulting in bioaccumulation and poses a 
potential risk to aquatic life, invertebrates and certain fish(65)
,
(56).  
In waste water effluents, there are present chlorated derivatives of triclosan 
present either during the waterwaste disinfection with chorine or by skipping 
the standard treatments, these chlorinated triclosan derivatives can cause more 
endocrine dysfunction in addition to more antibacterial action. Triclosan 
derived dioxins are also formed after triclosan containing water has been treated 
with chlorine and then exposed to UV irradiation. These dioxins are more toxic 
than their parent compounds and can further breakdown to form highly 
chlorinated toxic dioxins, which are harmful to aquatic life and fish(66).   
These environmental risks have contributed greatly in the past few years in 
raising bans against the indiscriminate use of triclosan. 
 
Target organisms:  
Triclosan has a broad spectrum of organisms that it is effective against 
including gram positive and gram negative non sporulating organisms. It is 
most effective against Staphylococci, some streptococci, few mycobacterium, 
enterococci and proteus species. It also has some fungicidal activity. Any 
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bacteria or micro-organism containing the FabI site on the enoyl-acyl reductase 
enzyme is susceptible to triclosan(57). Triclosan thus acts against organisms 
that colonize the skin and the oral cavity which when impregnated into medical 
devices and sutures may contribute to decreasing the risk of surgical site 
infections. Sutures, urinary catheters, central venous catheters and orthopaedic 
implants when impregnated with triclosan have been used and researched in the 
medical industry since the 1980s. 
Different microorganisms affected by the antimicrobial action of TCS(66). 
Target Microorganisms 
Effective 
Concentrations  
                       Most sensitive strains 
Staphylococci, some Streptococci, some mycobacteria, 
Escherichia coli, Klebsiella pneumonia, Klebsiella 
spp., Enterobacter spp., Acinetobacter spp., Proteus 
spp. and Proteus mirabilis, Plasmodium falciparum, 
Toxoplasma gondii 
0.01 mg·L
−1
 to 
0.1 mg·L
−1
 
 
 
 
 
 
Less sensitive strains   
Methicillin-resistant Staphylococcus aureus (MRSA) 
strains 
0.1–2 mg·L−1 
 
Enterococci - 
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Target Microorganisms 
Effective 
Concentrations  
  Highly resistant strains 
Pseudomonas aeruginosa, Clostridium difficile - 
 
 
Triclosan coated sutures:  
For over 30 years, the question whether sutures act as a nidus of wound 
contamination and infection has been debatable.   As with the use of any other 
biomedical implant, sutures too can cause tissue inflammation, microbial 
adherence and bacterial colonization. Bacterial affinity varies with the type of 
suture material used. Studies have shown that bacteria are more adherent to 
braided sutures like silk, polyglactin when compared to monofilament sutures 
like nylon. The bacterial organisms studied included Staphylococcus aureus, 
Staphylococcus epidermidis, Methicillin resistant staphylococcus aureus and 
Escherichia coli(67,68).  Tissue reactions occur when biomedical devices and 
suture material are introduced into the body. The surface of the suture gets 
coated by proteins as part of the tissue reaction, these proteins – fibronectin, 
fibrinogen and collagen which act as adhesions for bacteria(68).  Bacteria that 
colonize the skin surface may be introduced into the wound tracks, where skin 
colonizes like staph. Epidermidis can form a biofilm which confers protection 
upto the organism from the body‟s defense mechanisms. Triclosan is effective 
against the bacterial colonization and thus the formation of the biofilm.  
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The incorporation of triclosan into suture was found to perform the same if not 
better than the uncoated polyglactin. The intra-operative handling, the ease of 
throwing a knot, the holding of the first knot, the memory and its passage 
through tissues were studied and found to be the same as the plain uncoated 
polyglactin sutures(69)(70). There was a definitive difference in the immediate 
post operative pain in those where the coated sutures were utilized. Pain in the 
immediate post operative period is an indication of early sub-clinical infection, 
whether the decrease in the pain was due to inhibition of the colonization of the 
bacteria is left to speculation(69).    
 
Antibiotic Resistance:  
There have been many theories regarding the development of microbial 
resistance to triclosan. These include(66): 
- Overproduction of targets 
- Modification of the targets 
- Membrane permeability and barriers 
- Efflux pump(71)- as seen in Pseudomonas aeruginosa. 
- Over-expression of the target enzyme 
- Non susceptibility of the target enzyme or alteration to the FabI 
enzyme. 
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Pseudomonas is unique in that it possess both sensitive and resistant enzymes – 
FabI, FabK. It also has intrinsic resistance due to expression of multiple efflux 
systems. Only four such systems have been characterized of which the  
MexAB-OprM efflux system is responsible for triclosan resistance(71). E.Coli 
when exposed to triclosan is capable of selection of FabI mutants and causes 
overproduction of FabI which leads to an increase in the triclosan resistance. 
Strains of staphylococcus aureus which showed decreased sensitivity to 
triclosan were found to have a mutation in the FabI enzyme which resulted in 
overproduction of these strains(72)(73).   
Triclosan is a substrate of several MDR efflux pumps and may promote 
multidrug resistance in bacteria to both the antiseptic and antibiotics, thus 
compound antibiotic resistance. The fear of overuse of triclosan is cross-
resistance which will promote the emergence of super-bugs.  
Drug resistance in the laboratory and in the environment was different. Studies 
revealed that use of triclosan in hygiene products did not affect the nature of the 
oral flora or change their susceptibility to antibiotics.  There has been no 
established relationship between triclosan usage in practice and development of 
antibiotic resistance(74). The use of triclosan should be restricted and closely 
monitored as there exist a potential for resistance in the future. 
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Triclosan has no known mutagenic, carcinogenic or any associated toxicities. 
As the molecular structure closely resembles that of the thyroid and oestrogen 
molecules, there has been concern regarding disruption of the endocrine and 
reproductive axis. The potential hazards and risks are currently still currently 
being investigated by the EPA and the FDA.  
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METHODS 
A pilot study was done to determine the incidence of wound infection in consecutive 
cases that undergo surgery for oral malignancies with all surgical sites being closed 
with triclosan coated polyglactin 910 sutures from 1
st
 January 2014 to 31
st
 July 2015. 
Diagrammatic Algorithm of the study
 
All cases of oral malignancy 
undergoing elective surgery 
from 1st Jan 2013 to 31st July 
2015.
Study Group
Those who will undergo 
surgery from 1st Jan 2014 till 
31st July 2015 using Triclosan 
coated polyglactin sutures
Informed consent to be taken 
prior to surgery
Follow up at 6weeks or 
initiation of radiotherapy for 
wound infections
Incidence of wound infections 
and microbiological analysis 
Excluded : Those not willing for 
follow up or initiation of 
radiotherapy.
Comparsion Group
Those who underwent surgery 
from 1st Jan 2013 till 31st Dec 
2013 using Plain Polyglactin 
sutures
Consent taken during the 
previous year for use of 
information
Incidence of wound infection
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Methods in detail: 
i. Intervention and Comparator agent – Antimicrobial coated 
polyglactin sutures versus plain polyglactin sutures 
ii. Key Criteria 
Inclusion Criteria:  
- All patients undergoing elective surgery for oral malignancy. 
- Patients willing for  follow up at CMC, Vellore 
-  Patients willing to be followed up till initiation of radiotherapy. 
 
Exclusion Criteria:  
- Patients not consenting. 
- Patients not willing for follow up in our institution. 
- Patients not willing for radiotherapy at our institution. 
 
 
iii. Method of randomization:  
- All consecutive cases over a period of one and a half years, starting 
from 1
st
 January 2014 till 31
st
 July 2015. 
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iv. Method of allocation concealment: nil 
 
v. Blinding and masking: nil 
 
vi. Primary Outcome:   
 
- To determine the incidence of wound infection in both study  groups 
 
vii. Secondary Outcome/s:   
- To assess the duration of hospital stay. 
- To find the delay in initiation of radiotherapy in those with wound  
infection. 
- To do a microbiological analysis of the oral cavity in oral malignancy 
cases. 
- To evaluate the bacteriology of wound infections involved when 
operating these patients. 
 
viii. Target sample size and rationale:  
The sample size was calculated using the software nMaster 2.0 
The proportion in group A is 0.38(75)  
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The expected proportion in Group B is 0.20 
Risk Difference = 0.18 
Alpha error = 5% 
Power = 80% 
The minimal sample size required to compare the infection rates 
in both groups is = 90 
So total number  = 90 + 90 = 180 
So total sample size required for the study is 180. 
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The formula used for sample size calculation is: 
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RESULTS: 
A total of 53 patients were recruited for the study. The patients for the study 
were all recruited prior to surgery from the surgical wards and the outpatient 
department. 
PROFILE OF PATIENTS: 
 
 
 
The total cases recruited were 53, of which 31 (57%) were males. The total 
number of females included in the study was 22 (43%) as seen in Fig 1. 
57%
43%
Fig 1: Sex Distribution
Male
Female
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There were 42 patients equal to or above the age of 40 years(79%) which 
constituted the majority. The number of those below the age of 40 years was 11 
(21%). 
21%
79%
Fig 2: Age distribution
Less than 40 years
Equal to or more than 40 years
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Of all the patients recruited 60% of patients gave a positive history of tobacco 
usage either in the form of cigarette smoking, chewing of paan with tobacco or 
using a tobacco quid. 
 
 
 
60%
40%
Fig 3: Tobacco usage
History of tobacco usage presernt
No history of tobacco usage
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Of the total of 53 patients recruited, only 36% (19 patients) have good oral 
hygiene as documented by no oral cavities, plaques or staining of teeth. Of the 
53 patients, 57% of patients, 30 patients had bad or poor oral hygiene – 
presence of plaques, staining or dental caries. There were 4 patients of the total 
53 were edentulous. Whether or not the dental status was a cause for an 
increased infection rate was studied by doing a univariate analysis. 
 
36%
57%
7%
Fig 4: Dental status
Good oral hygiene
Poor oral hygiene
Edentulous oral cavity
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The oral cavity disease was assessed clinically and was staged according to the 
AJCC, TNM staging for oral malignancy. All the 53 patients, there were 41.5% 
diagnosed to have T2 and 26.4% were diagnosed to have T4 disease.  
 
 
 
 
 
 
T 1 T2 T3 T4 Tx
Stage of the disease - Clinical 
T(tumor)
12 22 4 14 1
0
5
10
15
20
25
N
u
m
b
e
r 
o
f 
p
at
ie
n
ts
Fig 5: Stage of the disease - Clinical T(tumor)
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Following clinical evaluation and staging by the AJCC TNM staging, 30 
(56.6%) patients had N0 disease. N1 disease was seen in 15.1% of total cases 
and N2 and N3 disease accounted for 26.4% and 1.9% of all cases 
respectively.(Figure 6). The relationship of the clinical nodal disease was 
compared with the infection rate in the univaritate analysis. 
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Fig 6: Stage of disease - Clinical N (Nodal)
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Figure 7 shows the frequency distribution of the patients in terms of the 
pathological T stage of the tumour. T1 cancers constituted 39.6%, T2 cancers 
accounted for 24.5% of all cases while T4 cancers accounted for a total of 
22.6%.  
 
 
 
 
T0 T1 T2 T3 T4
Stage of disease - Pathological T 
(tumour)
4 21 13 3 12
0
5
10
15
20
25
N
u
m
b
e
r 
o
f 
p
at
ie
n
ts
Fig 7: Stage of disease - Pathological T (tumour)
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Figure 8 shows the frequency distribution of the pathological N stage of the 
tumour. N0 cancers were seen in  54.7%,andN2 cancers accounted for 22.6% of 
all cases while  N1 cancers accounted for a total of 17.0%.  
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Fig 8: Stage of disease - Pathological N (nodal) 
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As seen in the Figure 9, the distribution of cases was recruited based on the type 
of surgery performed. Early lesions were treated with a wide local excision and 
primary closure. More advanced lesions required tumour resection with flap 
reconstructions and either unilateral or bilateral neck dissections. The flap 
reconstructions included both myocutaneous flap – pectoralis major, delto-
pectoral flap, – bi-paddle flap and microvascular free flaps – radial forearm free 
flap, fibula free flap. 
 
 
43%
57%
Fig 9: Operative procedure preformed
Wide local excision with primary 
closure
Tumour resections with flap 
reconstructions
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The majority of the oral cancers were squamous cell carcinoma as was 
consistent with other studies. Of all the patients recruited, 3 patients (6%) did 
not have any residual tumour either following preoperative chemoradiation or 
from previous wide local excisions with positive margins. 4 patients had non 
squamous pathology which included ameloblastoma, adenoid cystic carcinoma, 
verrucous carcinoma and rhabdomyosarcoma. 
 
87%
7%
6%
Fig 10: Histopathology of the resected tumour
Squamous cell carcinoma
Others
No residual tumour
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Triclosan coated polyglactin 3-0 suture on a cutting needle was used either in 
continuous or interrupted sutures to close all the intraoral suture lines. There 
was no change in the technique of the operative procedure when compared to 
the previous year. There was no difference in suture handling as reported by the 
operating surgeons when compared to uncoated polyglactin sutures. A total 
number of 53 patients were recruited for the study and a total of 9 patients 
developed a surgical site infection as per the definition by the Center for 
Disease Control. 
 
 
17%
83%
Fig 11: Occurrence of post operative infection while 
using triclosan coated sutures
Yes
No
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Univariate analysis: 
 
 
 
Stage of disease – 
clinical T (tumour) 
Infection occurred                       
(no of patients) 
No infection                                       
(no of patients) 
T1 1 11 
T2 1 21 
T3 2 2 
T4 5 9 
Table 1: Comparing the stage of the disease – clinical T stage with number of patients with infection 
 
As seen in Table 1, T4 tumours had the highest number of total patients with 
wound infection.The incidence of post-operative wound infection attained 
statistical significance as  the clinical stage of the tumour increased with P = 
0.024 (p<0.05, confidence interval = 95%).  
T1 T2 T3 T4
No infection 91.70% 95.50% 50% 64.30%
Infection occurred 8.30% 4.50% 50% 35.70%
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Fig 12: Comparing the stage of disease –
Clinical T (tumour) with occurrence of 
infection
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Table 2: Stage of the disease – pathological T with relation to the number of patients with wound infection 
 
Figure 2 shows the correlation of the pathological T-stage and the incidence of 
wound infection in the study population. These findings are in consistency with 
the causal relationship between the pathological T stage of the disease and the 
incidence of wound infection with p = 0.001 (confidence interval of 95%). 
T0 T1 T2 T3 T4
No infection 100% 95.20% 84.60% 0% 75%
Infection occurred 0% 4.80% 15.40% 100% 25%
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Fig13: Stage of disease - pathological T 
(tumour) and infection
Stage of disease – 
pathological T (tumour) 
Infection occurred                       
(no of patients) 
No infection                                       
(no of patients) 
T0 0 4 
T1 1 20 
T2 2 11 
T3 3 0 
T4 3 9 
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Table 3: Relationship between the total duration of hospitalization in relation to number of patients with 
surgical site infections 
 
The total duration of hospitalization is increased in those patients who have 
wound infections, this was statistically significant, p = 0.01 (p<0.05, confidence 
interval of 95%). The conclusion is that in those who have a wound infection 
required a longer duration of hospitalization and in effect an increase in the cost 
of treatment. The Table 3 shows that all the 9 nine patients who had post 
operative infections were admitted for a duration of more than 10 days. 
Less than 10 days of 
hospitalization
10 days or more of 
hospitalization
No infection 100% 74.30%
Occurrence of infection 0% 25.70%
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Fig14: Total duration of hospitalization in 
relation to surgical site infection
Total duration of 
hospital stay (days) 
Infection occurred                       
(no of patients) 
No infection                                       
(no of patients) 
Less than 10 days 0 18 
10 days or more  9 26 
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Table 4: Shows that all the patients with wound infections had received antibiotics 
 
There was an association with total duration of antibiotics and incidence of 
wound infections. The patients who received 48 hours of antibiotics also 
underwent less extensive surgeries, when compared to those who received more 
than 48 hours of antibiotics. for more than 48 hours, this was statistically 
significant with p = 0.01 (p<0.05, confidence interval of 95%). 
  
48 hours of antibiotics
More than 48 hours of 
antibiotics
No infection 100% 72.70%
Occurrence of infection 0% 27.30%
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Fig 15: Total duration of antibiotic 
adminstration and its relation to infection
Total duration of 
antibiotics 
Infection occurred                       
(no of patients) 
No infection                                       
(no of patients) 
48 hours of antibiotics 0 20 
More than 48 hours of 
antibiotics 
9 24 
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Table 5: Type of surgery performed in comparison to number of patients with infection 
 
As the extent of surgical resection increases there is an associated increase in 
the infection rate, p = 0.061 (p< 0.1, confidence interval of 90%). Those who 
underwent surgical resections with flap reconstructive surgeries are at a higher 
risk of wound infections. This includes reconstructions done with both 
myocutaneous flaps and micro-vascular free flaps.  The inference to check for 
statistical significance at 5 % can occur only once the total sample size is 
complete.  
Wide local excision with 
primary closure
Surgical resection with 
flap reconstruction
no infection 95.70% 73.30%
Occurrence of infection 4.30% 26.70%
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Fig 16: Comparsion of type of surgery 
performed to occurrence of infection
Type of surgery 
preformed 
Infection occurred                       
(no of patients) 
No infection                                       
(no of patients) 
Wide local excision 
with primary closure 
1 22 
Surgical resections with 
flap reconstruction 
8 22 
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Table 6: Comparison of intra-operative blood loss and its correlation to number of patients with infection. 
 
There was an increase in the number of patients with infection when there was 
more than 250ml of intra-operative blood loss, which was statistically 
significant at an alpha error of 20% ( p = 0.133) . Whether this is statistically 
significant at an alpha error of 5% can be determined only on completion of the 
proposed sample size. 
  
less than 250ml 250ml or more
No infection 94.70% 76.50%
Occurrence of infection 5.30% 23.50%
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Fig.17: Comparsion between total 
intraoperative blood loss and infection
Intraoperative blood 
loss 
Infection occurred                       
(no of patients) 
No infection                                       
(no of patients) 
Less than 250ml 1 18 
250ml or more 8 26 
73 
 
 
 
Stage of disease – 
clinical N (nodal) 
Occurrence of infection   
(no. of patients) 
No infection                  
(no. of patients) 
N0 3 27 
N1 1 7 
N2 5 9 
N3 0 1 
Table 7: Comparison of clinical stage of nodal disease with number of students with infections 
 
There was an association with an increase in wound infection rate as the clinical 
nodal stage increased (Table 7), though there was no statistical significance  
with p = 0.184. If allowable alpha error was taken as 20%, with a confidence 
interval of 80%, then p = 0.2, then clinical nodal disease would be statistically 
significant. As nodal disease increases so does the extent of surgery performed 
with more extensive nodal dissections. As the current sample size is inadequate 
N0 N1 N2 N3
No infection 90% 87.50% 64.30% 100%
Occurrence of infection 10% 12.50% 35.70% 0%
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Fig.18: Comparsion with clinical stage of 
nodal disease with infection 
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for this assessment, to fully understand the significance, it would warrant 
completion of the proposed study. 
 
 
 
Total duration of 
post operative stay 
Occurrence of infection   
(no. of patients) 
No infection                  
(no. of patients) 
Less than 7 days 0 10 
7 days or more 9 34 
Table 8: Comparison of infection rates with total duration of post operative stay 
There is an association between the occurrence of infection and an increase in 
the duration of post operative stay. The p value calculated from the above Table 
8 is 0.18, which on allowance of an alpha error of 20%, and a confidence 
interval of 80% is statistically significant. Significance at a confidence interval 
Less than 7 days 7 days or more
No infection 100% 79.10%
Occurrence of infection 0% 20.90%
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Fig. 19: Comparison of occurence of 
infection and total post operative duration 
of stay
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of 95% will require the completion of the proposed pilot study, as the sample 
size currently achieved is inadequate for this assessment. 
Multivariate analysis:  
On doing a multivariate analysis, there was no significant risk factor that was 
associated with an increased infection rate. To get any conclusive results the 
sample size will have to be completed following which analysis will have to be 
done. 
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There were multiple other factors that were studied but were found to be 
statistically insignificant. 
 
 Occurrence of infection 
(frequency/percentage) 
No infection 
(frequency/percentage) 
Male Sex 4 /12.9% 27 / 87.1% 
Female Sex 5 / 22.7% 17 / 77.3% 
Table 9: Comparison of sex distribution with incidence of infection 
Here in Table 9, the calculated p = 0.464 which was statistically insignificant.  
 
 
 
 Occurrence of infection 
(frequency/percentage) 
No infection 
(frequency/percentage) 
Less than 40 years 1 / 9.1% 10 / 90.9% 
40 years or more 8 / 19.0% 34 / 81.0% 
Table 10: Comparison of age of patients with incidence of infection 
The p value calculated from the Table 10was 0.665, which was not significant. 
Thus age had no bearing to incidence of wound infections. 
 
 
 
 
Occurrence of infection 
(frequency/percentage) 
No infection 
(frequency/percentage) 
Diabetic  1 / 20.0% 4 / 80.0% 
Non - diabetic 8 / 16.7% 40 / 83.3% 
Table 11: Comparison of history of diabetes and infection rates 
Here the calculated p = 1.000, which was more than 0.05 and was thus 
insignificant.(Table 11) 
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Occurrence of infection 
(frequency/percentage) 
No infection 
(frequency/percentage) 
Tobacco usage 4 /12.5% 28 / 87.5% 
No tobacco usage 5 / 23.8% 16 / 76.2% 
Table 12: Comparison of tobacco usage and its link to occurrence of infection 
The p value derived from the Table 12 was 0.456, these findings were 
statistically insignificant, and thus there was no relationship between tobacco 
use and occurrence of infection. 
 
History of 
chemotherapy/ 
Radiation 
 
Occurrence of infection 
(frequency/percentage) 
No infection 
(frequency/percentage) 
Yes 0 / 0% 3 / 100% 
No 9 / 18.0% 41 / 82.0% 
Table 13: Comparison of previous radiation therapy or chemotherapy with incidence of wound infection 
There was no increase in infection if there was history of previous 
chemotherapy or radiation. In the Table 12, the calculated p = 1.000 which was 
insignificant statistically.  
 
Hemoglobin 
(mg/dl) 
Occurrence of infection 
(frequency/percentage) 
No infection 
(frequency/percentage) 
Less than 8 0 / 0% 1 / 100% 
8 or more 9 / 17.3% 43 / 82.7% 
Table 14: Comparison of hemoglobin preoperatively of the patient with incidence of wound infection 
In Table 14, the calculated p = 1.000, this was less than 0.05 and was 
insignificant. The relationship between the pre-operative hemoglobin levels to 
occurrence of infection was absent. 
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Total platelets 
 
Occurrence of infection 
(frequency/percentage) 
No infection 
(frequency/percentage) 
Less than 4 lakh 3 / 10.7% 25 / 89.3% 
4 lakh or more 1 / 50.0% 1 / 50.0% 
Table 15: Comparison of total platelets preoperatively with incidence of wound infection 
In  Table 15, the calculated p = 0.253, which is statistically insignificant. There 
was thus no relationship between the total per-operative platelets and 
occurrence of infection. 
 
Initiation of 
radiation therapy  
Occurrence of infection 
(frequency/percentage) 
No infection 
(frequency/percentage) 
Less than 6 weeks 3 / 23.1% 10 / 7.9% 
 6 weeks or more  4 / 44.4% 5 / 55.5% 
Table 16: comparison of initiation of radiation therapy and infection 
In Table 16, the calculated p = 0.376, which is insignificant statistically. 
 
 
Histopathology of 
tumour 
 
Occurrence of infection 
(frequency/percentage) 
No infection 
(frequency/percentage) 
Squamous cell 
carcinoma 
9 / 19.6% 37 / 80.4% 
Others 0 / 0% 4 / 100% 
Table 17: Incidence of wound infection with difference in the histopathology of the tumour 
In the above Table 17, the calculated p = 1.000, and reveals no relationship 
between the incidence of wound infection and histo-pathological report of the 
tumour in itself.  
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MICROBIOLOGICAL ANALYSIS:  
Oral swabs were taken preoperatively prior to administration of antibiotics in 
the operation theatre. In those individuals who developed wound infections, 
cultures were taken from the site of the infection and sent for analysis. 
 
 
SL.NO PRE-OPERATIVE POST – OPERATIVE 
1. Staphylococcus aureus Enterobacter, staphylococcus aureus 
2. Pseudomonas aeruginosa Pseudomonas aeruginosa 
3. Enterobacter Alpha hemolytic streptococcus 
4. Pseudomonas aeruginosa, 
Klebsiella 
Klebsiella, Enterobacter  
5. Escherichia coli, streptococcus Staphylococcus, Streptococcus 
6. Normal oral flora Staphylococcus 
7. Beta hemolytic streptococcus Staphylococcus aureus, Escherichia coli 
8. 
 
Non-hemolytic streptococcus, 
staphylococcus aureus, 
Fusobacterium 
Streptococcus 
9. Klebsiella Escherichia coli, non fermenting gram 
negative bacilli 
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In additional to the above organisms, there were also cultures that grew normal 
oral flora in the midst of oral malignancy. Whether more extensive oral lesions 
have a more varied oral flora is left to speculations and would require further, 
more extensive in detail evaluation.  
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DISCUSSION: 
In our pilot study, 53 patients were recruited of which only 9 patients developed 
wound infections post operatively. This accounted for 17% during the course of 
the study. Prior to this, during the period of January 2013 to December 2013, a 
total of 88 operations for oral malignancies were done in our department, of 
which 21 (23.86%) patients had post operative wound infection. This was found 
to be statistically insignificant with a p=0.33 at the current sample size of 53 
patients. The true statistical significance is awaited completion of the proposed 
sample size. 
 Triclosan coated sutures have found applications during the closure of the 
subcutaneous layer in major abdominal surgeries.  Multiple studies have been 
done with varying conflicting results.  In a case control study performed by 
Rasic Z et al, 184 patients were recruited with colorectal cancers, for 91 
patients, triclosan coated polyglactin sutures were utilized. There were 12 
patients who developed surgical site infections, the use of the coated sutures 
was shown to decrease wound infection in addition to total post operative 
duration of stay(76). Another multicenter randomized PROUD trial published 
in The Lancet in July 2014, found that incorporating triclosan into 
polydioxanone sutures did not reduce the incidence of surgical site 
infections(77).  Wang et al conducted a systemic review and meta-analysis on 
17 randomised control trials were 3720 patients were recruited. He found that 
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there was a 30% reduction in the total surgical site infections with the use of 
triclosan coated sutures(78). A meta-analysis was done to assess the prevention 
of infections following incision closure with Triclosan coated sutures. Daoud et 
al carried out the meta-analysis which included 15 randomized control trials 
with 4,800 study subjects. The results of the analysis suggest strongly that the 
presence of triclosan within the incision site was an important factor 
responsible for a decrease in the incidence of surgical site infections(79). It has 
also been clearly stated that in view of inadequate number of trial that include 
the operation type and the definition of a surgical site infection, it is prudent to 
continue these studies after considering these factors(79).   
The cause for infections is multifactorial and there appears no one answer to 
why infections occur. These factors may either be patient related or other 
extrinsic factors. In our study, there was an increase in wound infection rate as 
the clinical T stage of the tumour increased, with 5 patients with T4 disease 
having wound infection, where p = 0.001 ( p<0.5, CI 95%). This was 
statistically significant and consistent with findings by Penel et al(19) and 
Robbins et al(45).  For all oral malignancies, patients have been advised to take 
prophylactic antibiotics. In our unit, for all early stage lesions, Metronidazole 
and Salbactum – Cerfeperazone were given for a duration of 48 hours. For 
Stage III and IV disease, the antibiotics were continued for 5 days. In our study, 
we found that those who received antibiotics for more than 48 hours had an 
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increased wound infection rate, p = 0.01 (p<0.5, CI 95%) as was reported by 
Lofti et al(75). These patients are also those who had higher staged tumours and 
more extensive surgical dissections.  
An increase in the total duration of hospital stay was seen in patients who had 
wound infections, all nine patients who had a surgical site infection had a total 
duration of hospital stay of more than 10 days, p = 0.01 (p<0.5, CI 95%). The 
increases in duration of hospital stay also lead to an increase in the total hospital 
expenses which was not quantified in this study.  
In patients who underwent surgical resections with flap reconstructions, there 
was an increase in the surgical site infection, p = 0.061 (p<0.1, CI 90%), similar 
findings were reported by Belusic-Gobic et al, where a retrospective study was 
done with 111 patients(18). Lofti et al also reported similar findings in a 
prospective study done which included 258 patients.  There was also an 
association noted between total intraoperative blood loss and infection rate, p = 
0.133(p<0.2, CI 80%). Lofti et al conducted a prospective study of 258 patients 
in order to identify a high risk group for wound infections, there was no 
association found with relation to intraoperative blood loss or intraoperative 
blood transfusion(75). There was also a strong association with occurrence of 
infection and the clinical nodal staging of the disease, with p= 0.184 (p<0.2, CI 
80%). This finding was confirmed by Robbins et al who studied 400 cases at 
the M. D Anderson Cancer Center to determine risk factors in head and neck 
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patients, their conclusion was that the N stage is predictive of infection. These 
findings were confirmed further by Lofti et al. Belusic-Gobic did not find any 
association between N stage of the disease and infection rates.  
The N stage disease and the total intraoperative blood loss were associated with 
increase in wound infection at a confidence interval of 80%, to be statistically 
significant at 95% the proposed sample size would require completion. 
Schwartz found that there was an increase in wound infection rate with 
thrombocytosis (48), which was in contrast to the findings in our study.  
In our study age, sex, diabetic status or consumption of tobacco had no bearing 
on wound infection rates. The dental status in our study had no association on 
infections which differed from Chaukar et al prospective study of 186 
patients(52). 
Whether preoperative chemotherapy or radiation would affect the surgical site 
and cause infections was always debatable. In our study, of the 53 recruited 
only 1 case had both chemotherapy and radiation preoperatively, there was no 
association found, as was confirmed by other studies(17,46). Penel in his study 
showed no association between radiation and wound infection but significance 
was present for preoperative chemotherapy. Girod et al in a retrospective study 
of 159 patients found that preoperative radiation therapy significantly increases 
the post-operative complications(47).  
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The swabs that were taken from the infected wounds exhibited polymicrobial 
infection, as was also confirmed by various other studies where there were 
similar culture growths as shown in the table below: 
 
Author Organisms cultured 
Chaukar et al(52) Escherichia coli, Pseudomonas aeruginosa 
Cloke et al(17) Staphylococcus sps, streptococcus, 
pseudomonas, Proteus, Escherichia coli 
Lofti et al(75) Pseudomonas, staphylococcus aureus, 
Escherichia coli, Klebsiella 
Belusic- Gobic et al(18) Staphylococcus aureus, Pseudomonas, 
Actinetobacter, Diphteroides 
Penel et al(19) Escherichia coli, Staphylococcus, streptococcus 
Table 18: Studies showing post operative wound cultures.  
 
In our study, out of the total 9 patients who developed wound infection, the 
organisms that were cultured from the infected wound of 5 patients post 
operatively were also noted in their preoperative oral cultures. Whether there is 
a role for preoperative intravenous antibiotics or as local mouthwashes should 
be strongly considered. 
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All 53 patients that were recruited for the study had pre-operative oral swabs 
taken prior to the administration of intravenous antibiotics. Culture growths 
included in additional to normal oral flora, the numerous pathological 
organisms that had the potential to cause wound related complications.  
Normal oral flora Pathological 
organisms with no 
infection 
Pathological 
organisms with 
infection 
Total oral swabs 
collected 
28 (52.8%) 15 (28.3%) 9 (16.9%) 53(100%) 
 
There were a total of 24 patients who grew pathological organisms in their pre-
operative cultures, of these only 9 patients had a post operative wound 
infection. There were 15 patients who did not have any post operative wound 
infection, the cause for which can be attributed to either the prophylactic 
antibiotics or use of triclosan suture coated material intra-operatively.  Of the 9 
patients who had a surgical site infection post operatively, 50% of the infections 
were caused by the same organisms that were cultures preoperatively. Whether 
this calls for further optimization of antibiotic protocols is a cause for further 
investigations. Studies are currently being formulated in our unit for 
development of these protocols. 
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LIMITATIONS: 
1. During the duration of the intended study, there was difficulty in 
procuring the required suture material – Triclosan coated polyglactin 
suture (Vicryl Plus) from the specific company on time. The net delay 
led to not being able to complete the sample size by the time of 
submission of this thesis. The intent is to complete the sample size, so as 
to provide statistical evidence. 
2. There are multiple confounding factors that can cause surgical site 
infections, only a few of which have been studied in this study. Studying 
all the factors though important would have been beyond the scope of 
this study. Further more comprehensive studies have to be carried out to 
fully understand the complexity of wound infections. 
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CONCLUSION:  
The overall wound infection rate in post operative patients who underwent oral 
malignancies surgery with the use of triclosan coated polyglactin sutures was 
17%. As the clinical and the pathological T staging increased, the incidence of 
wound infection also increased. This was statistically significant with p = 0.009 
(p <0.05, confidence interval -95%). There was also statistical significance in 
relation to total duration of hospital stay and infection with p=0.02 (p <0.05, 
confidence interval -95%). The total duration of antibiotic administration was 
also significant with those having antibiotics for more than 48hours having a 
higher risk of infection. Confounding factors were not included as major head 
and neck dissections received more than 48 hours of antibiotics while wide 
local excision with primary closure were given only 48 hours of antibiotics. An 
increase in the risk of infection was also associated with the surgery preformed, 
the total intra-operative blood loss and the clinical nodal disease prior to 
surgery. Multivariate analysis was inconclusive and would require completion 
of the proposed sample size. 
The microbiological analysis revealed that the oral microbiology in patients 
with an oral malignancy is the same as those without. The cultures revealed 
normal oral flora in addition to pathological organisms such as Staphylococcus, 
Streptococcus and Klebsiella, Enterobacter. In wounds that were infected, there 
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was a similarity in the pre operative culture and cultures taken from the infected 
site.   
  
This pilot study reveals that post operative wound infection rate in patients with 
oral malignancy had decreased when triclosan coated sutures were used for 
surgical closure as compared to those with plain polyglactin 910 sutures, the 
true statistical significance of the proposed sample size is awaited on 
completion of the study. Nevertheless, this pilot study reveals that tumour 
staging of disease is a statistical significant factor to determine post operative 
surgical site infections. 
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PROTOCOL 
1. Case recruitment, with consent taking from the ward on Monday. 
2. ON THE DAY OF SURGERY: 
Prior to administration of antibiotics – 2 oral swab to be taken 
 
Details regarding- Intraoperative blood loss, lowest intraoperative 
temperature recording and transfusions to be filled online in operation 
record. 
 
  
3. POST- OPERATIVELY: 
 Should wound infection occur, 2 oral swabs to be taken. 
 
WOUND INFECTION DEFINED BY CDC CRITERIA INCLUDED IN THE 
STUDY AS BELOW: 
Infection occurs within 30 days post op, must involve at least one of the following: 
 
1.  Purulent drainage from the superficial incision. 
2.  Organisms isolated from an aseptically obtained culture of fluid or tissue from 
the superficial incision. 
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3.   At least one of the following: pain, tenderness, localized swelling, redness, 
heat and superficial incision is deliberately opened by surgeon, unless incision is 
culture-negative. 
4. Diagnosis of superficial incisional SSI by the surgeon or attending physician. 
Do not report the following conditions as SSI: 
1. Stitch abscess (minimal inflammation and discharge confined to the points of  
2. suture penetration). 
3. Incisional SSI that extends into the fascial and muscle layers. 
 
 
 
 
 
 
 
 
 
 
 
 
102 
 
STUDY PROFORMA: 
DATE OF RECRUITMENT: __________________  
SERIAL NO: ________________ 
NAME: _________________________________   
HOSPITAL NO: ____________________ 
SEX:_________   AGE: _________ 
HISTORY OF DIABETES MELLITUS: Y/N 
 IF YES, CONTROLLED OR UNCONTROLLED: 
_____________________________ 
HISTORY OF TOBACCO USAGE:  
______________________________________________ 
PREVIOUS HISTORY OF CHEMOTHERAPY:  
____________________________________ 
PREVIOUS HISTORY OF RADIATION  
THERAPY:_________________________________ 
CURRENT DENTAL STATUS (good, bad, edentulous): 
_______________________________ 
PREOPERATIVE INVESTIGATIONS: 
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HEMOGLOBIN: 
________________________________________________________ 
TOTAL PLATELETS: 
____________________________________________________ 
STAGING OF THE DISEASE: Clinical – 
___________________________________________ 
       Pathological - 
______________________________________________    
SURGERY PROFORMED: 
_____________________________________________________________________
________ 
 
DATE OF SURGERY: 
__________________________________________________________ 
ORAL SWAB TAKEN PREOPERATIVELY ON TABLE: Y/N  
TOTAL DURATION OF SURGERY: 
______________________________________________ 
TOTAL INTRAOPERATIVE BLOOD LOSS: 
_______________________________________ 
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LOWEST INTRAOPERATIVE TEMPERATURE 
RECORDED:_________________________ 
OCCURRENCE OF INFECTION: Y/N 
 IF YES, SWAB TAKEN: Y/N 
TOTAL DURATION OF HOSPITAL 
STAY:________________________________________ 
TOTAL DURATION OF POST OPERATIVE 
STAY:__________________________________ 
ANTIBIOTICS ADMINISTERED: 
________________________________________________ 
TOTAL DURATION OF ANTIBIOTIC ADMINSTRATION: 
__________________________ 
INITIATION OF 
RADIATHERAPY:______________________________________________ 
 
PREOPERATIVE CULTURE GROWTH :  
_____________________________________________________________________
_________ 
105 
 
_____________________________________________________________________
_________ 
_____________________________________________________________________
________ 
 
CULTURE GROWTH FROM INFECTED SITE: 
_____________________________________________________________________
_________ 
_____________________________________________________________________
_________ 
_____________________________________________________________________
________ 
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INFORMATION SHEET 
 
Thank you for considering to participate in this study. Given here are details 
pertailing to the study. Should you have any other questions do not hesitate to ask.  
 
WHAT IS THE PURPOSE OF THE STUDY? 
Head and neck cancers are very common in our country and those operated are at a 
risk of developing wound infection. The risk of wound infection is relatively high, 1 in 
4 individuals are prone to develop wound infection. The factors that cause wound 
infection are still unclear. The introduction of perioperative antibiotics has decreased 
the risk of infections. This study aims to determine whether an antibiotic coated 
suture will reduce the risk further. 
Triclosan sutures have decreased surgical site infections by 30%, but no studies have 
been done using Triclosan sutures in oral malignancy – thus this study. 
 
WHAT IS TRICLOSAN? 
Tricolsan is an antimicrobial compound that acts by preventing reproduction of 
microorganisms. It was introduced initially into soaps and detergents as an 
antibacterial substance which prevents local colonization. 
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HOW DOES IT WORK? 
When it is incorporated into sutures, Triclosan prevents bacterial colonization of the 
suture line and the surrounding area where there is local absorption of the 
antimicrobial into the tissue. 
ANY ADVERSE EFFECTS OF USING TRICLOSAN? 
Studies have not shown any evidence of skin sensitisation, or any other adverse 
effects and no difference in intraoperative handling by surgeons. 
 
WHAT IS MY ROLE AS A PATIENT? 
The role you play by agreeing to participate in this study is by ensuring to follow up in 
our hospital for radiotherapy in those where it is indicated or otherwise a period of 6 
weeks. 
 
HOW DOES THE STUDY PROCEED? 
Once the participant has agreed to be part of the trial and the written consult is given 
there will be the standard pre- operative blood investigations done.  
Intraoperatively, the participant will receive the first dose of antibiotics which will be 
continued for the total of 5 days postoperatively as is the unit policy. Postoperatively 
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should a participant get a wound infection, microbiological samples will be taken and 
they will be treated for the same. 
 
WILL THERE ANY ADDED EXPENSES? 
All expenses conferred in this study – additional cost of suture materials will be 
covered by external funding. Should a wound infection occur, the expenses of the 
bacterial culture will be covered by these external funds. 
No additional expenses will be imposed on the participant. 
 
WHAT HAPPENS IF THERE IS AN UNTOWARD EVENT? 
If there is any untoward event – that is an allergic reaction to suture material or any 
other unprecedented reaction, you can freely withdraw from the study and expenses 
will covered by unit fund. 
Wound infection, sepsis is not considered as an untoward event. 
 
 
 
 
In case of any queries, please contact :  
Dr. Abhilasha Singh,  
Tel no : 9894047520 
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CONSENT FORMS 
Informed Consent form to participate in a research study 
Study Title:  Use of triclosan coated polyglactin 910 sutures versus plain                                          
polyglactin 910 sutures in oral malignancy. 
Study Number: ____________ 
Subject’s Initials: _________  Subject’s Name: 
_________________________________________ 
Date of Birth / Age: ___________________________ 
 
(Subject) 
 
(i)  I confirm that I have read and understood the information sheet dated 
____________ for the above study and have had the opportunity to ask 
questions.  
 
(ii)  I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care or 
legal rights being affected.  
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(iii)  I understand that the Sponsor of the clinical trial, others working on the 
Sponsor‟s behalf, the Ethics Committee and the regulatory authorities will not 
need my permission to look at my health records both in respect of the current 
study and any further research that may be conducted in relation to it, even if I 
withdraw from the trial. I agree to this access. However, I understand that my 
identity will not be revealed in any information released to third parties or 
published.  
 
(iv)  I agree not to restrict the use of any data or results that arise from this study 
provided such a use is only for scientific purpose(s). 
 
(v)  I agree to take part in the above study.  
 
 
Signature/ Thumb impression of the Participant :  
 
Date: _____/_____/______ 
 
Signatory‟s Name: __________________________         Signature:  
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Signature of the Investigator:   Signature of the Witness:  
 
 
Date: _____/_____/_____     Date: _____/_____/_____ 
Study Investigator‟s Name: _______________  Name & Address of the 
Witness 
 
 
In case of any queries, please contact :  
Dr. Abhilasha Singh,  
Tel no : 9894047520 
 
Master Data Sheet 
 
 
SERIAL 
NO. SEX AGE DM 
DM 
STATUS TOBACCO CHEMO RT 
DENTAL 
STATUS HB PLATELET 
CLI  
- T 
CLI 
- N 
PATH 
- T 
PATH 
- N SURGERY DURATION 
BLOOD 
LOSS 
HOSPITAL 
STAY 
POST 
OP 
STAY 
DURATION 
OF ABX 
STARTING 
RT PATHOLOGY INFECTION 
1 1 2 2 0 1 2 2 2 2 0 2 5 4 1 2 2 2 2 2 2 2 1 1 
2 1 2 2 0 1 2 2 1 2 0 2 5 1 5 1 1 2 2 2 2 0 1 2 
3 1 2 1 1 1 2 2 2 2 0 1 5 1 5 1 
  
1 1 1 0 1 2 
4 1 2 2 0 2 2 2 1 2 1 1 5 5 5 1 1 1 1 1 1 0 0 2 
5 2 2 2 0 2 2 2 3 2 0 2 5 5 5 1 2 1 1 2 1 0 0 2 
6 1 2 2 0 1 2 2 1 2 1 2 5 1 5 1 1 1 2 2 2 2 0 2 
7 1 1 2 0 2 2 2 1 2 0 1 5 1 5 2 2 2 1 2 1 0 2 2 
8 2 2 2 0 1 2 1 2 2 1 2 1 1 5 2 2 2 2 2 2 0 1 2 
9 2 2 2 0 1 2 2 2 2 0 4 1 4 2 2 2 2 2 2 2 1 1 2 
10 1 1 2 0 2 1 2 1 2 2 2 5 1 5 1 1 1 2 2 2 1 2 2 
11 2 1 2 0 1 2 2 2 2 0 1 5 2 5 1 2 1 1 1 1 2 1 2 
12 2 2 2 0 1 2 2 2 2 1 4 2 1 2 2 2 2 1 2 2 2 1 2 
13 2 2 2 0 1 2 2 2 2 0 4 1 2 5 2 2 2 2 2 2 1 1 1 
14 1 2 2 0 2 2 2 1 2 1 4 5 2 5 2 2 2 2 2 2 2 1 2 
15 2 2 2 0 1 2 2 2 2 0 2 5 2 2 1 2 2 1 2 2 0 1 2 
16 1 2 2 0 1 2 2 1 2 1 4 1 4 2 2 2 2 2 2 1 1 1 2 
17 1 2 2 0 1 2 2 1 2 1 2 5 1 5 1 2 1 1 2 2 2 1 2 
19 2 2 2 0 1 2 2 2 2 1 2 1 1 1 1 2 1 2 1 1 1 1 2 
20 1 2 2 0 2 2 2 1 2 1 4 2 2 5 2 2 2 2 2 2 1 1 2 
21 2 2 2 0 1 2 2 3 2 1 0 2 1 1 1 2 2 2 2 2 1 1 2 
22 2 2 1 2 2 2 1 2 2 1 4 2 5 1 2 2 2 1 2 2 0 1 2 
23 2 2 2 0 1 2 2 2 1 1 3 1 4 5 2 2 2 2 2 2 0 1 2 
24 1 2 2 0 2 2 2 1 2 1 2 5 4 5 1 2 2 2 2 2 0 1 2 
25 2 2 2 0 1 2 2 2 2 0 2 5 1 5 1 2 2 1 1 1 0 2 2 
26 1 2 2 0 2 2 2 2 2 0 1 5 1 5 1 1 1 1 1 1 0 2 2 
27 2 2 1 2 1 1 2 2 2 1 4 3 4 2 2 2 2 2 2 2 0 1 2 
28 2 1 2 0 2 2 2 2 2 1 3 2 3 0 2 2 2 2 2 2 2 1 1 
29 1 2 2 0 1 2 2 2 2 0 1 5 2 5 1 2 1 1 1 1 0 1 2 
Master Data Sheet 
 
 
 
SERIAL 
NO. SEX AGE DM 
DM 
STATUS TOBACCO CHEMO RT 
DENTAL 
STATUS HB PLATELET 
CLI  
- T 
CLI 
- N 
PATH 
- T 
PATH 
- N SURGERY DURATION 
BLOOD 
LOSS 
HOSPITAL 
STAY 
POST 
OP 
STAY 
DURATION 
OF ABX 
STARTING 
RT PATHOLOGY INFECTION 
30 2 1 2 0 1 2 2 2 2 1 2 5 1 3 1 1 1 1 2 1 0 1 2 
31 1 1 2 0 1 2 2 2 2 0 1 5 1 2 1 1 1 1 1 1 0 1 2 
32 2 2 2 0 1 2 2 1 2 2 4 2 4 2 2 2 2 2 2 2 0 1 1 
33 1 1 2 0 1 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 0 1 2 
34 1 1 2 0 1 2 2 1 2 1 2 5 1 1 1 2 2 1 1 2 0 1 2 
35 2 2 2 0 2 2 2 2 2 0 4 5 2 5 2 2 2 2 2 2 2 1 1 
36 1 1 2 0 2 2 2 1 2 1 1 5 5 5 1 1 1 1 2 2 0 1 2 
37 1 2 2 0 1 2 2 2 2 1 2 1 4 5 2 2 2 2 2 2 0 1 2 
38 2 2 2 0 1 2 2 3 2 0 2 5 2 5 2 2 2 2 2 1 0 1 2 
39 1 2 2 0 1 2 2 2 2 1 1 5 1 5 1 2 2 1 1 1 0 1 2 
40 1 2 2 0 1 2 2 2 2 0 4 2 3 2 2 2 2 2 2 2 1 1 1 
41 1 2 1 2 1 2 2 2 2 1 4 2 4 2 2 2 1 2 2 2 0 1 2 
42 1 2 2 0 2 2 2 1 2 1 1 5 1 5 1 1 1 2 2 2 0 1 1 
43 2 2 2 0 2 2 2 1 2 0 2 5 2 5 2 1 1 2 2 2 0 1 2 
44 2 1 2 0 2 2 2 1 2 0 1 5 1 5 2 2 2 2 2 2 0 1 2 
45 1 2 2 0 1 2 2 2 2 0 2 5 1 2 2 2 2 2 2 2 1 1 2 
46 1 2 2 0 2 2 2 1 2 0 2 2 2 1 2 2 2 2 2 1 0 1 2 
47 1 2 2 0 2 2 2 1 2 1 2 5 4 1 1 1 1 2 2 1 1 1 2 
48 2 2 1 2 2 2 2 2 2 0 3 2 4 1 2 2 2 2 2 2 1 1 1 
49 1 1 2 0 1 2 2 2 2 0 2 1 2 5 2 2 2 2 2 1 0 1 2 
50 2 2 2 0 2 1 1 3 2 0 1 5 1 0 2 2 1 2 2 1 0 1 2 
51 1 2 2 0 2 2 2 1 2 1 4 2 3 5 2 2 2 2 2 2 2 1 1 
52 1 2 2 0 2 2 2 2 2 1 2 5 1 5 1 2 1 1 2 1 0 1 2 
53 1 2 2 0 1 2 2 2 2 1 3 2 2 2 2 2 2 2 2 1 1 1 2 
54 1 2 2 0 1 2 2 2 2 1 4 2 4 1 2 2 2 2 2 2 1 1 2 
 ABSTRACT: 
OBJECTIVES: 
To study post operative wound infection rates in patients with oral malignancy 
following use of antimicrobial coated polyglactin 910 sutures as compared to plain 
polyglactin 910 sutures.  
 
METHODS: A pilot study of consecutive cases that underwent surgery for oral malignancies 
with all surgical sites being closed with triclosan coated polyglactin 910 sutures from 1
st
 
January 2014 to 31
st
 July 2015. A total number of 53 patients were recruited and oral swabs 
was taken and sent for microbiological analysis prior to antibiotic administration. The overall 
wound infection rate was then compared retrospectively to the infection rate in the previous 
year in patients where the surgical sites sutured with plain polyglactin 910. Independent 
variables were analyzed by Chi-Squared test; multiple logistic regression was preformed to 
account for multiple risk factors.   
 
RESULTS & CONCLUSIONS: The overall wound infection rate in post operative 
patients who underwent oral malignancies surgery with triclosan coated polyglactin 
sutures was 17%. The wound infection rate had decreased from 23.86% when plain 
polyglactin sutures were used. Multivariate analysis was inconclusive and requires 
completion of the proposed sample size. 
 
 
 The microbiological analysis revealed that the oral microbiology in patients with an 
oral malignancy is the same as those without.  
Nevertheless, this pilot study reveals that tumour staging of disease is a statistical 
significant factor to determine post operative surgical site infections. 
 
KEYWORDS : Triclosan, wound infection, oral malignancy  
 
